PURPOSE:Antiangiogenic agents combined with chemotherapy have efficacy in the treatment of unresectable malignant pleural mesothelioma (MPM). Cediranib (AstraZeneca, Cheshire, United Kingdom), a vascular endothelial growth factor receptor and platelet-derived growth factor receptor inhibitor, demonstrated therapeutic potential in a prior phase I trial. We evaluated a phase II trial for efficacy. PATIENTS AND METHODS: SWOG S0905 (ClinicalTrials.gov identifier: NCT01064648) randomly assigned cediranib or placebo with platinum-pemetrexed for six cycles followed by maintenance cediranib or placebo in unresectable chemotherapy-naïve patients with MPM of any histologic subtype. Primary end point was Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 progression-free survival (PFS). Secondary end points included overall survival, PFS by modified RECIST v1.1, response (modified RECIST and RECIST v1.1), disease control, and safety/toxicity. The trial was designed to detect a difference in RECIST v1.1 PFS at the one-sided 0.1 level using a stratified log-rank test. RESULTS:Ninety-two eligible patients were enrolled (75% epithelioid and 25% biphasic or sarcomatoid). The cediranib arm had more grade 3 and 4 diarrhea, dehydration, hypertension, and weight loss. Cediranib improved PFS by RECIST v1.1 (hazard ratio, 0.71; 80% CI, 0.54 to 0.95; P = .062; 7.2 months v 5.6 months) and increased modified RECIST v1.1 response (50% v 20%; P = .006). By modified RECIST v1.1, cediranib numerically increased PFS (hazard ratio, 0.77; 80% CI, 0.59 to 1.02; P = .12; median, 6.9 months v 5.6 months). No significant difference in overall survival was observed. CONCLUSION: The addition of cediranib to platinum-pemetrexed improved PFS by RECIST v1.1 and response rate by modified RECIST in patients with unresectable MPM. Whereas adding antiangiogenics to chemotherapy has been a successful strategy for some patients, the cediranib toxicity profile and small incremental survival benefit precludes additional development in MPM.
RCT Entities:
PURPOSE: Antiangiogenic agents combined with chemotherapy have efficacy in the treatment of unresectable malignant pleural mesothelioma (MPM). Cediranib (AstraZeneca, Cheshire, United Kingdom), a vascular endothelial growth factor receptor and platelet-derived growth factor receptor inhibitor, demonstrated therapeutic potential in a prior phase I trial. We evaluated a phase II trial for efficacy. PATIENTS AND METHODS: SWOG S0905 (ClinicalTrials.gov identifier: NCT01064648) randomly assigned cediranib or placebo with platinum-pemetrexed for six cycles followed by maintenance cediranib or placebo in unresectable chemotherapy-naïve patients with MPM of any histologic subtype. Primary end point was Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 progression-free survival (PFS). Secondary end points included overall survival, PFS by modified RECIST v1.1, response (modified RECIST and RECIST v1.1), disease control, and safety/toxicity. The trial was designed to detect a difference in RECIST v1.1 PFS at the one-sided 0.1 level using a stratified log-rank test. RESULTS: Ninety-two eligible patients were enrolled (75% epithelioid and 25% biphasic or sarcomatoid). The cediranib arm had more grade 3 and 4 diarrhea, dehydration, hypertension, and weight loss. Cediranib improved PFS by RECIST v1.1 (hazard ratio, 0.71; 80% CI, 0.54 to 0.95; P = .062; 7.2 months v 5.6 months) and increased modified RECIST v1.1 response (50% v 20%; P = .006). By modified RECIST v1.1, cediranib numerically increased PFS (hazard ratio, 0.77; 80% CI, 0.59 to 1.02; P = .12; median, 6.9 months v 5.6 months). No significant difference in overall survival was observed. CONCLUSION: The addition of cediranib to platinum-pemetrexed improved PFS by RECIST v1.1 and response rate by modified RECIST in patients with unresectable MPM. Whereas adding antiangiogenics to chemotherapy has been a successful strategy for some patients, the cediranibtoxicity profile and small incremental survival benefit precludes additional development in MPM.
Authors: Anne S Tsao; Linda Garland; Mary Redman; Kemp Kernstine; David Gandara; Edith M Marom Journal: J Thorac Oncol Date: 2011-03 Impact factor: 15.609
Authors: Anne S Tsao; James Moon; Ignacio I Wistuba; Nicholas J Vogelzang; Gregory P Kalemkerian; Mary W Redman; David R Gandara; Karen Kelly Journal: J Thorac Oncol Date: 2017-06-06 Impact factor: 15.609
Authors: Linda L Garland; Kari Chansky; Antoinette J Wozniak; Anne S Tsao; Shirish M Gadgeel; Claire F Verschraegen; Marco A Dasilva; Mary Redman; David R Gandara Journal: J Thorac Oncol Date: 2011-11 Impact factor: 15.609
Authors: Ralf Erber; Andreas Thurnher; Alice D Katsen; Gesine Groth; Heinz Kerger; Hans-Peter Hammes; Michael D Menger; Axel Ullrich; Peter Vajkoczy Journal: FASEB J Date: 2003-12-04 Impact factor: 5.191
Authors: Federica Grosso; Nicola Steele; Silvia Novello; Anna K Nowak; Sanjay Popat; Laurent Greillier; Thomas John; Natasha B Leighl; Martin Reck; Paul Taylor; David Planchard; Jens Benn Sørensen; Mark A Socinski; Ute von Wangenheim; Arsène Bienvenu Loembé; José Barrueco; Nassim Morsli; Giorgio Scagliotti Journal: J Clin Oncol Date: 2017-09-11 Impact factor: 44.544
Authors: Y Ohta; V Shridhar; R K Bright; G P Kalemkerian; W Du; M Carbone; Y Watanabe; H I Pass Journal: Br J Cancer Date: 1999-09 Impact factor: 7.640
Authors: Patrick M Forde; Valsamo Anagnostou; Zhuoxin Sun; Suzanne E Dahlberg; Hedy L Kindler; Noushin Niknafs; Thomas Purcell; Rafael Santana-Davila; Arkadiusz Z Dudek; Hossein Borghaei; Mara Lanis; Zineb Belcaid; Kellie N Smith; Archana Balan; James R White; Christopher Cherry; I K Ashok Sivakumar; Xiaoshan M Shao; Hok Yee Chan; Dipika Singh; Sampriti Thapa; Peter B Illei; Drew M Pardoll; Rachel Karchin; Victor E Velculescu; Julie R Brahmer; Suresh S Ramalingam Journal: Nat Med Date: 2021-11-08 Impact factor: 53.440